By targeting RAS-driven cancers thatdisplay high amounts of cleaved CDCP1 with antibody-drug conjugates,BiTES, and radionuclide-antibody conjugates, we have shown that theseantibodies provide a greater therapeutic index.138,363 With emerging information on precise cell surface cleavage sites(neo-N-termini), biologics that target proteolytic neo-epitopes isan exciting therapeutic landscape. Here, CDCP1 is linked to cancer.